fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Ofloxacin

All products: Limited Use (codes 170)

Ocuflox · DIN 02143291 · 0.3% · Oph Sol

Limited Use, Reason for Use code 170 requiredMarketed · checked November 18, 2026
StatusLimited Use, Reason for Use code 170 required
Write on scriptReason for Use code 170 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Ontario Limited Use criteria, code 170
Reason for Use code 170 For the treatment of conjunctivitis caused by susceptible strain(s) of Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pneumoniae and Hemophilus influenzae which is/are resistant or unresponsive to listed alternative agents. Coverage limit: LU Authorization Period: 1 year
No interchangeable product listed in the Ontario extract
Ocuflox · DIN 02143291 Manufacturer: Allergan Inc.; listing date 1996-12-19 Health Canada: Marketed since 2024-05-27 · brand OCUFLOX · ATC S01AE01 OFLOXACIN · form Solution · route Ophthalmic · ingredients OFLOXACIN 0.3 %/W/V · company Summer fridays llc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Ocuflox: Formulary list price $2.87 per unit (the source does not state the unit; exact figure $2.8720). What the ministry pays, not the patient.

Ministry pays: $2.8720 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02143291)

Source record
DIN 02143291: Ocuflox Raw flags: sec12=Y, sec3=Y Item: 520412008; group id 587; item number 1544; lccId 00080; manufacturer id ALL Source form: Oph Sol; strength: 0.3% Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $2.8720; ministry $2.8720 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02143291 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=18491
Shortage status: not checked (no credentials)

Other products in the same Health Canada class (S01AE): coverage varies; not interchangeable

  • Ciprofloxacin (Ciloxan): not a benefit
Other drugs in the same formulary class (52:04:12 Other Anti-Infectives) and how they are covered

Matched class: 52:04:12 Other Anti-Infectives

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. No displayed product is listed as a general benefit in this extract. Check its listing requirements below. 52:04:12 Other Anti-Infectives

CIPROFLOXACIN

· 3 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 0.3% · Oph Sol-5mL Pk Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 52:04:12
Full class listing Related classes: 52:04:04 Antibiotics, 52:08:92 Anti-Inflammatory Agents, Miscellaneous Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS OCUFLOX® (ofloxacin) is indicated for the treatment of conjunctivitis when caused by susceptible strains of the following bacteria: Gram Positive Bacteria • Staphylococcus aureus • Staphylococcus epidermidis • Streptococcus pneumoniae Gram Negative Bacteria • Haemophilus influenza To reduce the development of drug-resistant bacteria and maintain the effectiveness of OCUFLOX and other antibacterial drugs, OCUFLOX should be used only to treat infections that are proven or strongly suspected to be caused by bacteria. 1.1 Pediatrics Pediatrics (< 18 years of age): Based on the data submitted and reviewed by Health Canada, the safety and efficacy of OCUFLOX in pediatric patients has not been established. Therefore, Health Canada has not authorized an indication for pediatric use. See 7.1.3 Pediatrics. 1.2 Geriatrics Geriatrics (> 65 years of age): No comparative data are available to Health Canada; therefore, Health Canada has not authorized an indication for geriatric use. https://pdf.hres.ca/dpd_pm/00067076.PDF PM date: NOV 25, 1994 Source product: OCUFLOX; DIN 02143291; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.